Dydrogesterone is named as an intervention in 2 current clinical trials in our China and Turkey registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is The University of Hong Kong (1). The most-studied condition is Subfertility.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET
NCT03859921 · ClinicalTrials.gov ↗ · Subfertility
|
Phase 3 | Recruiting | The University of Hong Kong | China |
|
Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy
NCT07496294 · ClinicalTrials.gov ↗ · Menopausal Women, Menopausal Symptom Relief, Hormone Therapy
|
Not applicable | Not yet open | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | Turkey |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Dydrogesterone on the HPRA medicines list.
No entry for Dydrogesterone in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| The University of Hong Kong | 1 |
| Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Turkey | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Turkey registers name Dydrogesterone as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The University of Hong Kong (1) and Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Dydrogesterone, for example Duphaston 10 mg film-coated tablets (Theramex Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Dydrogesterone has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dydrogesterone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dydrogesterone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dydrogesterone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.